Daprodustat

(Jesduvroq®)

Jesduvroq®

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormTablet (oral: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg)
Drug ClassHypoxia-inducible factor prolyl hydroxylase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Daprodustat (Jesduvroq) is recommended for the treatment of anemia due to chronic kidney disease in adults undergoing dialysis for at least four months. It demonstrates similar efficacy to recombinant human erythropoietin (rhEPO) and other erythropoiesis-stimulating agents (ESAs) in managing anemia, with no significant differences in hemoglobin level changes observed between nondialysis-dependent and dialysis-dependent patient subgroups.
  • Twelve studies were reviewed, providing insights into Jesduvroq's effectiveness compared to ESAs and hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs).
  • Compared to ESAs, Jesduvroq was associated with slightly improved hemoglobin levels and significantly reduced incidence of major adverse cardiovascular events (MACE) and myocardial infarction, particularly within the dialysis-dependent subgroup, positioning it as a safer alternative.
  • Jesduvroq demonstrated significant increases in transferrin saturation, total iron-binding capacity, and total iron compared with rhEPO, suggesting potential advantages in optimizing iron metabolism, especially within patients dependent on dialysis.
  • The safety profile for daprodustat appears favorable when compared against both ESAs and placebo. There was no increase in serious adverse events overall; however, minor side effects such as diarrhea were reported more frequently than in those taking ESAs.
  • When comparing daprodustat's effectiveness in managing hemoglobin levels against other HIF-PHIs like roxadustat, although somewhat less effective, it showed lower risks related to hypertension or thrombosis complications, making it a potentially safer option among this drug class.
  • Among nondialyzed CKD patients, Jesduvroq significantly reduced hepcidin levels – crucial for proper iron metabolism – showing promise as an effective treatment alternative over darbepoetin alfa.
  • In terms of subgroup considerations, Jesduvroq's effects closely matched overall trends observed for other HIF-PHIs. However, it showed specific improvements in cardiovascular outcomes and iron metabolism parameters within certain CKD patient subgroups, making it a potentially more beneficial treatment option.

Product Monograph / Prescribing Information

Document TitleYearSource
Jesduvroq (daprodustat) Prescribing Information. 2023GlaxoSmithKline., Durham, NC

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. 2023Frontiers in Pharmacology
Safety and efficacy of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. Erythropoietin-stimulating agents in treating anemia in renal patients (with or without Dialysis): a meta-analysis and systematic review. 2023Cureus
A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. 2023Aging
Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis.2023Frontiers in Endocrinology
Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.2022European Journal of Clinical Pharmacology
Efficacy and safety of daprodustat Vs rhEPO for anemia in patients with Chronic Kidney Disease: a meta-analysis and trial sequential analysis. 2022Frontiers in Pharmacology
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease. 2022The Cochrane Database of Systematic Reviews
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis. 2022Clinical and Experimental Nephrology
Safety of daprodustat in patients with anemia of chronic kidney disease: a pooled analysis of phase 3 studies in Japan. 2022Therapeutic Apheresis and Dialysis
Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients. 2021Journal of Clinical Pharmacy and Therapeutics
Efficacy and safety of daprodustat for anemia therapy in Chronic Kidney Disease patients: a systematic review and meta-analysis. 2021Frontiers in Pharmacology
Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. 2020Renal Failure